Accelerate Diagnostics (NASDAQ:AXDX) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a research report released on Thursday morning.

Accelerate Diagnostics Stock Performance

AXDX stock traded down $0.02 during midday trading on Thursday, reaching $1.85. The company had a trading volume of 25,482 shares, compared to its average volume of 82,394. The stock has a 50 day moving average price of $1.77 and a 200 day moving average price of $1.46. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $5.78.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. increased its holdings in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the period. Griffin Asset Management Inc. owned approximately 6.26% of Accelerate Diagnostics worth $1,615,000 at the end of the most recent quarter. Institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.